FDA approves pralsetinib for RET-altered thyroid cancers

The U.S. Food and Drug Administration approved pralsetinib (Gavreto; Blueprint Medicines Corporation) for advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy or RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate), according to a press release. The approval is for adult and pediatric patients ≥12 years old.

Read the full press release here.

SOURCE: U.S. Food and Drug Administration